Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Dianthus Therapeutics (DNTH) Assets Average (2018 - 2025)

Dianthus Therapeutics has reported Assets Average over the past 7 years, most recently at $451.8 million for Q3 2025.

  • Quarterly results put Assets Average at $451.8 million for Q3 2025, up 24.93% from a year ago — trailing twelve months through Sep 2025 was $451.8 million (up 24.93% YoY), and the annual figure for FY2024 was $276.7 million, up 110.81%.
  • Assets Average for Q3 2025 was $451.8 million at Dianthus Therapeutics, up from $337.3 million in the prior quarter.
  • Over the last five years, Assets Average for DNTH hit a ceiling of $451.8 million in Q3 2025 and a floor of $81.0 million in Q2 2023.
  • Median Assets Average over the past 4 years was $185.9 million (2023), compared with a mean of $245.4 million.
  • Biggest five-year swings in Assets Average: crashed 56.14% in 2023 and later skyrocketed 363.61% in 2024.
  • Dianthus Therapeutics' Assets Average stood at $123.6 million in 2022, then surged by 50.41% to $185.9 million in 2023, then surged by 95.84% to $364.1 million in 2024, then rose by 24.07% to $451.8 million in 2025.
  • The last three reported values for Assets Average were $451.8 million (Q3 2025), $337.3 million (Q2 2025), and $361.3 million (Q1 2025) per Business Quant data.